SAN DIEGO --(BUSINESS WIRE)--Jan. 19, 2023-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its fourth quarter and full year 2022 results after the financial markets close on Wednesday, February 22, 2023 .
SAN DIEGO --(BUSINESS WIRE)--Jan. 10, 2023-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, today reported its preliminary, unaudited sales for the fourth quarter and year ended December 31, 2022 and worldwide sales outlook for the year ending
SAN DIEGO --(BUSINESS WIRE)--Jan. 3, 2023-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at the 41 st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at
Acquisition Expands Addressable Market Opportunity and Complements Family of Insulin Delivery Offerings Conference Call Tuesday, December 13, 2022 at 8:00am ET SAN DIEGO --(BUSINESS WIRE)--Dec. 13, 2022-- Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology
SAN DIEGO --(BUSINESS WIRE)--Nov. 16, 2022-- Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, is proud to announce its Great Place to Work Certification™, a prestigious award based entirely on results from in-depth employee surveys around their
SAN DIEGO --(BUSINESS WIRE)--Nov. 10, 2022-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, announced results from a prospective, multicenter, single-arm study of adults living with type 2 diabetes who achieved improvement in all clinical
SAN DIEGO --(BUSINESS WIRE)--Nov. 8, 2022-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at the Piper Sandler 34 th Annual Healthcare Conference on Wednesday, November 30, 2022 at
SAN DIEGO --(BUSINESS WIRE)--Nov. 2, 2022-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended September 30, 2022 and updated its financial guidance for the year ending December 31, 2022 .
SAN DIEGO --(BUSINESS WIRE)--Oct. 27, 2022-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at the following investor conferences: Credit Suisse 31 st Annual Healthcare Conference
SAN DIEGO --(BUSINESS WIRE)--Oct. 4, 2022-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its third quarter 2022 results after the financial markets close on Wednesday, November 2, 2022 .
SAN DIEGO --(BUSINESS WIRE)--Aug. 22, 2022-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at the following investor conferences: 2022 Wells Fargo Healthcare Conference on
SAN DIEGO --(BUSINESS WIRE)--Aug. 18, 2022-- Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, today announced that t:slim X2 insulin pump users have delivered more than 1 million insulin boluses using the t:connect app feature on their personal
SAN DIEGO --(BUSINESS WIRE)--Aug. 3, 2022-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended June 30, 2022 and updated its financial guidance for the year ending December 31, 2022 .
SAN DIEGO --(BUSINESS WIRE)--Jul. 21, 2022-- Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, today announced its acquisition of infusion set developer, Capillary Biomedical. “Infusion sets provide people flexible options in insulin pump
SAN DIEGO --(BUSINESS WIRE)--Jul. 12, 2022-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its second quarter 2022 results after the financial markets close on Wednesday, August 3, 2022 .
SAN DIEGO --(BUSINESS WIRE)--Jun. 16, 2022-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, today announced the appointments of Myoung Cha and Joao Malagueira as independent members of its board of directors effective June 15, 2022 .
NEW ORLEANS --(BUSINESS WIRE)--Jun. 6, 2022-- Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, announced positive real-world data demonstrating immediate and sustained benefits in a diverse cohort of people using the t:slim X2™ insulin pump with
SAN DIEGO --(BUSINESS WIRE)--May 18, 2022-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, today announced that management will present a company update at the Piper Sandler Virtual Diabetes Symposium on Wednesday, May 25, 2022 at 11:00am
SAN DIEGO --(BUSINESS WIRE)--May 4, 2022-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended March 31, 2022 and updated its financial guidance for the year ending December 31, 2022
BARCELONA, Spain --(BUSINESS WIRE)--Apr. 27, 2022-- Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, announced real-world data confirming that use of the t:slim X2™ insulin pump with Control-IQ® advanced hybrid closed-loop technology resulted in
